Business

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central

articleAxsome Therapeutics, Inc.May 1, 20254/company/axsome-therapeutics-inc/news/axsome-therapeutics-and-mental-health-america-mha-join-voices-highlight-mental-health
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

About this update from Axsome Therapeutics, Inc.

[{"type":"text","content":"NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May’s Mental Health Month. On May 1, as part of Mental Health America’s “Light Up Green” initiative, Axsome’s New York City headquarters, the One World Trade Center building, will be lit in green, the color for mental health awareness, and through the building’s Spireworks program. “Mental Health America’s 2024 data confirm what we already know to be true: We are in a mental health crisis that can affect anyone, anywhere,” said Schroeder Stribling, president and CEO of Mental Health America. “Mental health is health, and it affects us all. There are many social and environmental stressors impacting individuals and families across the country—whether you’re someone who lives in a remote rural community, a young person facing online bullying, or someone who is bearing the weight of family financial strain, one’s mental health is directly impacted. We hope that our Mental Health Month resources shine a light on these issues and support the needs of those who are seeking to understand and improve their mental health.” The impact of mental health conditions is significant in the United States, with nearly 1 in 4 adults in the U.S. living with a mental illness.1 More than 1 in 8 people aged 12 or older in the U.S. felt depressed in the past two weeks, according to a recent study, highlighting the ubiquity and significant impact that depression has in the U.S.2 In particular, nearly 90% of people living with depression report at least some difficulty with work, home or social activities due to their symptoms, contributing to the challenge of keeping up with day-to-day life.2 Axsome’s mission is to improve the lives of individuals living with serious CNS conditions that are difficult to treat or have limited treatment options by developing innovative evidence-based treatments that offer meaningful improvements to the standard of care. And, in the spirit of this year’s Mental Health Month theme of “Turning Advocacy into Action,” Axsome is highlighting the following resour...

More updates from Axsome Therapeutics, Inc.